Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi To Offer Broad Metabolic Syndrome Support Program For Acomplia

Executive Summary

Sanofi-Aventis is positioning Acomplia as part of a comprehensive cardio-metabolic disease management program that includes patient and physician support services

You may also be interested in...



Zimulti Loses On Weight Loss; Sanofi May Try Diabetes Route To Get Approval

If FDA concurs with the Endocrinologic and Metabolic Drugs Advisory Committee's negative opinion of the pending obesity indication for Zimulti (rimonabant), Sanofi-Aventis may have another attempt at bringing the drug to market for type 2 diabetes

Zimulti Loses On Weight Loss; Sanofi May Try Diabetes Route To Get Approval

If FDA concurs with the Endocrinologic and Metabolic Drugs Advisory Committee's negative opinion of the pending obesity indication for Zimulti (rimonabant), Sanofi-Aventis may have another attempt at bringing the drug to market for type 2 diabetes

Sanofi’s rimonabant from A to Z

The Endocrinologic and Metabolic Drugs Advisory Committee will convene June 13 to discuss efficacy and safety data for Sanofi-Aventis' potential first-in-class obesity agent rimonabant. The proposed trade name for the CB-1 receptor agonist, previously known as Acomplia in the U.S., is Zimulti. The committee will review rimonabant's use as an adjunct to diet and exercise for obesity management in patients. Sanofi announced in February that FDA extended rimonabant's user fee date by three months, which would set a late July user fee action date (1"The Pink Sheet" Feb. 19, 2007, p. 19). The meeting will take place at the Hilton in Silver Spring, Md., from 8 a.m. to 5 p.m...

Related Content

UsernamePublicRestriction

Register

PS048059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel